Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26724542 | 0.79 | CHRM2 (0.37) | BLMPMP22HSD17B10ALDH1A1 | |
| SCHEMBL24864488 | 0.79 | HDAC3 (0.33) | — | |
| SCHEMBL17853275 | 0.76 | ALDH1A1 (0.53) | BLMPMP22HSD17B10ALDH1A1 | |
| SCHEMBL18768950 | 0.76 | ALDH1A1 (0.53) | BLMPMP22HSD17B10ALDH1A1 | |
| SCHEMBL17853276 | 0.76 | ALDH1A1 (0.53) | BLMPMP22HSD17B10ALDH1A1 | |
| SCHEMBL17776318 | 0.76 | ALDH1A1 (0.53) | BLMPMP22HSD17B10ALDH1A1 | |
| SCHEMBL18769029 | 0.76 | ALDH1A1 (0.53) | BLMPMP22HSD17B10ALDH1A1 | |
| SCHEMBL22198371 | 0.76 | ALDH1A1 (0.53) | BLMPMP22HSD17B10ALDH1A1 | |
| SCHEMBL22198424 | 0.76 | ALDH1A1 (0.53) | BLMPMP22HSD17B10ALDH1A1 | |
| SCHEMBL10086608 | 0.76 | ALDH1A1 (0.53) | BLMPMP22HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| WO-2023280227-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | BLM 2617/4885PMP22 2940/4885HSD17B10 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.